Intravenous Use of Gammaglobulin in 1984

  • J. B. Bussel
Part of the Developments in Hematology and Immunology book series (DIHI, volume 13)

Abstract

Intravenous use of gammaglobulin therapy has been proven to be a major advance over intramuscular therapy in certain settings. This difference is due completely to consideration of dosage; the antibodies themselves are identical and come from identical sources of plasma and Cohn fractions. This increased dosage has expanded potential for antibody replacement and also has led to new application to the treatment of autoimmune disease.

Keywords

Toxicity Hepatitis Lymphoma Leukemia Fractionation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hill LE, Mollison PL. Conclusions. In: Hypogammaglobulinemia. United Kingdom Medical Research Council; MRC Special Report Series, no. 310, 1971.Google Scholar
  2. 2.
    Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human gammaglobulin. Vox Sang 1962; 7: 157–62.PubMedCrossRefGoogle Scholar
  3. 3.
    Ammann AJ, Ashman RF, Buckley RH et al. Use of intravenous gammaglobulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin Immunol Immunopathol. 1982; 22: 60–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Nolte MT, Pirofsky B, Gerritz GA, Golding B. Intravenous immunoglobulin therapy of antibody deficiency. Clin exp Immunol 1979; 36: 237–43.PubMedGoogle Scholar
  5. 5.
    Cunningham-Rundles C, Siegal FP, Smithwick EM et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann of Intern Med 1984; 101: 435–9.Google Scholar
  6. 6.
    Gelfand E. Treatment of chronic infections in hypogammaglobulinemia with very high dose intravenous gammaglobulin. In: Intravenous immunoglobulin in immunodeficiency syndromes and in ITP. Ed: Webster ADB, and Waters AH. Int Congress and Symposium Series. Pub: Roy Soc Med, London; 1985.Google Scholar
  7. 7.
    Von Muralt G, Sidiropoulos D. Le traitement substitutif par les immunoglobulines en neonatologie. la Presse Med 1983; 12: 2595–602.Google Scholar
  8. 8.
    Gordon DS, Hearn EB, Spira TJ, Reimer CB, Phillips DJ, Schable C. Phase I study of intravenous gammaglobulin in multiple myeloma Am J Med 1984; 76: 111–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Sulliser JM, Imbach P, Barandun S, et al. Varicella and herpes zoster in immunosuppressed children: preliminary results of treatment with intravenous immunoglobulin. Helv Pediatr Acta 1984; 39: 63–70.Google Scholar
  10. 10.
    Condie RM, O’Reilly RJ. Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Am J Med 1984; 76: 134–41.PubMedCrossRefGoogle Scholar
  11. 11.
    Nydegger UE, Blaser K, Hassig A. Antiidiotypic immunosuppression and its treatment with human immunoglobulin preparations. Vox Sang 1984; 47: 92–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Lever AML. The role of opsonic antibody in host defence. In: Intravenous immunoglobulin in immunodeficiency syndromes and in ITP. ED: Webster ADB, and Waters AH. Int Congress and Symposium Series. Roy Soc Med, London; 1985.Google Scholar
  13. 13.
    Imbach P, d’Apuzzi V, Hirt A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;i:1228.CrossRefGoogle Scholar
  14. 14.
    Bussel JB, Imberly RP, Inman RD, et al. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983; 62: 480–6.PubMedGoogle Scholar
  15. 15.
    Bussel J, Morell A, Porges A, et al. Selective IgG deficiency in patients with ITP. Abstract. ASH, 1984.Google Scholar
  16. 16.
    Bussel J, Porges A, Pahwa S, et al. Intravenous gammaglobulin in ITP: Effect on antibody synthesis. Abstract. ASH, 1983.Google Scholar
  17. 17.
    Tsubakio T, Kurata Y, Katagiri S, et al. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gammaglobulin therapy in patients with idiopathic thrombocytopenic purpura. Clin exp Immunol 1983; 53: 697–702.PubMedGoogle Scholar
  18. 18.
    Nilsson IM, Sundqvist SB. Suppression of secondary antibody response by intravenous immunoglobulin and development of tolerance in a patient with haemophilia B and antibodies. Scand J Haematol 1984; 33: 203–6.CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

  • J. B. Bussel

There are no affiliations available

Personalised recommendations